110 related articles for article (PubMed ID: 21499896)
1. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
Tsimberidou AM; Lewis N; Reid T; Burris H; Urban P; Tan EY; Anand S; Uehara C; Kurzrock R
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1507-16. PubMed ID: 21499896
[TBL] [Abstract][Full Text] [Related]
2. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
3. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
4. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
[TBL] [Abstract][Full Text] [Related]
5. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
[TBL] [Abstract][Full Text] [Related]
7. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
8. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
Tsimberidou AM; Takimoto CH; Moulder S; Uehara C; Mita M; Mita A; Urban P; Tan E; Wang Y; Vining D; Kurzrock R
Mol Cancer Ther; 2011 Jan; 10(1):209-17. PubMed ID: 21220503
[TBL] [Abstract][Full Text] [Related]
9. Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.
Haberer LJ; McSherry I; Cargill A; McCarthy L
Eur J Clin Pharmacol; 2014 Jan; 70(1):37-45. PubMed ID: 24100471
[TBL] [Abstract][Full Text] [Related]
10. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects.
Greene SA; Kwak C; Kamin M; Vernillet L; Glenn KJ; Gabriel L; Kim HW
Clin Transl Sci; 2022 Apr; 15(4):899-911. PubMed ID: 34877801
[TBL] [Abstract][Full Text] [Related]
11. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
13. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M
Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546
[TBL] [Abstract][Full Text] [Related]
15. A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
Treijtel N; Collins C; van Bruijnsvoort M; Fuhr R; Ernault E; Gangaram-Panday S; Passier P
Clin Pharmacol Drug Dev; 2019 May; 8(4):529-540. PubMed ID: 30730615
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
Sager JE; Lutz JD; Foti RS; Davis C; Kunze KL; Isoherranen N
Clin Pharmacol Ther; 2014 Jun; 95(6):653-62. PubMed ID: 24569517
[TBL] [Abstract][Full Text] [Related]
17. Effect of a traditional Chinese medicine Liu Wei Di Huang Wan on the activities of CYP2C19, CYP2D6 and CYP3A4 in healthy volunteers.
Chen Y; Ouyang DS; Kang Z; Yang GP; Tan ZR; Zhou G; Yan J
Xenobiotica; 2012 Jun; 42(6):596-602. PubMed ID: 22208477
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.
Bertilsson L; Tybring G; Widén J; Chang M; Tomson T
Br J Clin Pharmacol; 1997 Aug; 44(2):186-9. PubMed ID: 9278208
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.
Rocha A; Coelho EB; Moussa SA; Lanchote VL
Eur J Clin Pharmacol; 2008 Sep; 64(9):901-6. PubMed ID: 18581106
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans.
Elbe A; Foerster KI; Blank A; Rose P; Burhenne J; Haefeli WE; Mikus G
Eur J Clin Pharmacol; 2022 Jun; 78(6):975-987. PubMed ID: 35238961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
